Guardian Pharmacy Services (NYSE:GRDN) FY Conference Summary Company Overview - **Company**: Guardian Pharmacy Services - **Industry**: Healthcare Services, specifically focused on pharmacy services for assisted living facilities Key Points Business Performance and Momentum - Strong momentum exiting Q4 2025, primarily driven by vaccine clinics and acquisitions in the Pacific Northwest [2][3] - Successful management of vaccine clinics post-COVID, optimizing purchasing, reimbursement, and labor [2] - Acquisitions have leveraged synergies in national accounts, purchasing platforms, and revenue cycle management [3] Guidance and Future Outlook - Early guidance raised due to confidence in overcoming IRA headwinds, with strong vaccine clinic performance anticipated to continue into Q4 2026 [4] - Potential upside factors include increased acuity and better-than-expected performance from M&A and startups [5] Impact of IRA (Inflation Reduction Act) - Revenue impact from IRA projected to decrease from approximately $150 million in 2026 to $60-65 million in 2027, with further reductions in 2028 [8] - Company aims to mitigate EBITDA impact and return to normal metrics as the business stabilizes [8] M&A Strategy - M&A pipeline remains robust, with a focus on attractive geographies and operators willing to collaborate with Guardian [16][17] - Both M&A and contiguous startups are pursued concurrently to scale the business [18][19] - Recent acquisitions in Seattle and Oregon are performing ahead of schedule due to strong team capabilities and national account interest [21] Industry Trends and Demographics - Significant demographic trends with the aging population, particularly the baby boomer cohort turning 80, expected to drive demand in assisted living [26] - Anticipation of new building developments as occupancy rates approach levels that necessitate expansion [27] Innovative Programs and Technology - Early-stage pilot programs like falls risk prevention show promising results, utilizing clinical expertise and data analytics [30] - Guardian Shield program tracks clinical interventions and ensures medication regimens align with payors' formularies, resulting in cost savings for residents [31][32] - AI is being leveraged to enhance operational efficiency and improve service delivery [33] Financial Health and Capital Deployment - Strong cash conversion ratio of approximately 60%, with no debt on the balance sheet [36] - Future capital deployment strategies include continued M&A, strategic opportunities, and potential share buybacks [36][37] Regulatory Environment - Ongoing focus on drug pricing regulations, with efforts to align reimbursement algorithms with dispensing rates [39] - Participation in the Omnicare bankruptcy process presents potential opportunities for Guardian [40] Conclusion - Guardian Pharmacy Services is positioned for growth with a strong operational foundation, strategic M&A activities, and a favorable demographic trend in the assisted living sector. The company is actively managing regulatory challenges while innovating through technology and clinical programs to enhance service delivery and operational efficiency.

Financial Data and Key Metrics Changes - For Q2 2025, revenue grew 15% to $344.3 million, driven by solid low double-digit organic growth and contributions from recent acquisitions and greenfields [22] - Adjusted EBITDA was $25 million, up 15% year over year, with margins holding steady at 7.2% [23] - Adjusted EPS came in at $0.23, and the company maintained adjusted EBITDA margins at 7.2%, consistent with the prior year [6][22] - Cash position increased by approximately $4.8 million from Q1, ending the quarter with $18.8 million in cash [23] Business Line Data and Key Metrics Changes - Resident count increased 12% to over 195,000 [22] - The company added three new pharmacies this quarter, two via acquisition and one greenfield startup [9][10] - The recent acquisitions and greenfield startups are expected to account for a high single-digit percentage of 2025 revenue but will not contribute to EBITDA for the full year [26][27] Market Data and Key Metrics Changes - The company is expanding its presence in high-growth markets, including a new pharmacy in Naples, Florida, and acquisitions in Kansas and Washington [9][10] - The company anticipates typical seasonality in Q4 driven by COVID and flu vaccine activity, which turned profitable last year [24] Company Strategy and Development Direction - The company is focused on disciplined expansion into attractive high-growth markets and views M&A as an attractive use of capital [7][10] - The company is committed to operational excellence and customized service tailored to the communities served [10] - The long-term growth thesis remains intact, with a focus on organic growth, strategic greenfield opportunities, and a robust acquisition pipeline [21][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in funding future growth with internally generated cash and highlighted the strong year-to-date performance [6][7] - The company is proactively addressing changes in the policy environment, particularly regarding the Inflation Reduction Act and its impact on drug pricing [14][15] - Management remains optimistic about the ability to resolve pricing challenges and is engaged in constructive discussions with PBMs [18][19] Other Important Information - The company completed a non-dilutive secondary offering, nearly doubling its public float and improving trading dynamics [13] - The company recorded $1.1 million in costs associated with being a public company that did not exist in the prior year quarter [23] Q&A Session Summary Question: Is the vaccine program at a steady state or is there still potential for growth in Q4? - Management indicated that the vaccine program is at a steady state with general growth of the overall business [33] Question: When do PBM negotiations typically conclude? - Management stated that they are making good progress in negotiations and will update guidance as they approach Q4 [34] Question: Has being a public company changed the prospects or visibility of the company? - Management noted that increased visibility in public markets is a strong affirmation of the company and its services [36] Question: Can you elaborate on the organic growth drivers? - Management highlighted that organic growth is driven by share gain, patient acuity, and more complex drug regimens [43] Question: What is the current state of the acquisition pipeline? - Management confirmed that the acquisition pipeline remains strong, with human capital being the main limiting factor [44][45] Question: Can you provide figures on the recent managed healthcare pharmacy acquisition? - Management described the acquisition as typical in size and expressed excitement about the leadership team and market opportunities [48] Question: What is the expected resident count by the end of Q3? - Management indicated that they will continue the organic growth trajectory and layer in the impact of recent acquisitions [57]